# MARCH 10-13 2023

# 11<sup>th</sup> Annual Hematology and Medical Oncology Board Review

CONTEMPORARY PRACTICE



Memorial Sloan Kettering Cancer Center



"Excellent program! Appreciated the speakers, the pace, and the attention to time."

-2022 Attendee

## **Overview**

Condensed over three and a half days, this virtual course will provide an up-to-date and comprehensive review of the diagnosis, staging, and management of neoplastic disease, including solid tumor and hematologic oncology.

Lectures will focus on diseasespecific topics in gastrointestinal, gynecologic, thoracic, head and neck, genitourinary, soft tissue and skin, and central nervous system oncology, as well as hematologic oncology.

## **OBJECTIVES**

(1) Define state-of-the-science in diagnosis, staging, and therapeutic management of solid tumor cancers and hematologic cancers.

(2) Discuss recent treatment advances in solid tumor and hematologic oncology and apply knowledge gained in modern clinical practice.

(3) Prepare for ABIM examinations in medical oncology and hematology.

## TARGET AUDIENCE

The target audience for this wellreceived annual program includes medical oncology professionals (physicians, nurses, pharmacists, fellows and residents).

## SYLLABUS

Registered attendees will receive access to an online syllabus after the course, which includes select **PDFs of the faculty presentations** (slides) and recorded videos from the course.

## VIRTUAL FORMAT

This live virtual course will be delivered using Zoom. **CME credit** and **ABIM MOC points** will be offered. Detailed access and credit instructions will be emailed to attendees prior to the start of the program.

### **MSK COURSE DIRECTORS**





#### DAVID H. ILSON, MD, PHD, FACP, FASCO

Attending Physician, Member, Gastrointestinal Oncology Service; Professor of Medicine, Weill Cornell Medical College

#### PAUL A. HAMLIN, MD

Medical Director, David H. Koch Center for Cancer Care; Attending Physician, Lymphoma Service; Associate Professor of Medicine, Weill Cornell Medical College

## **MSK COURSE FACULTY**

**GHASSAN K. ABOU-ALFA, MD, MBA** Attending Physician, Gastrointestinal Oncology Service

**CAROL AGHAJANIAN, MD** Attending Physician, Chief, Gynecologic Medical Oncology Service

LIOR Z. BRAUNSTEIN, MD Assistant Attending Radiation Oncologist, External Beam Radiotherapy Service

#### ANDREA CERCEK, MD

Section Head, Colorectal Cancer; Co-Director, Center for Young Onset Colorectal and Gastrointestinal Cancers; Associate Attending Physician, Gastrointestinal Oncology Service

PAUL B. CHAPMAN, MD

Attending Physician, Melanoma Service

#### NOURA J. CHOUDHURY, MD

Assistant Attending Physician, Thoracic Oncology Service & Early Drug Development Service

#### HIRAM S. CODY III, MD, FACS

Attending Surgeon, Breast Service; Professor of Surgery, Weill Cornell Medical College

#### CHAU T. DANG, MD

Regional Care Network Medical Site Director, MSK Westchester; Attending Physician, Breast Medicine Service

#### MARK A. DICKSON, MD

Associate Attending Physician, Sarcoma Medical Oncology Service

#### LARA A. DUNN, MD

Assistant Attending Physician, Head and Neck Oncology Service

#### DARREN R. FELDMAN, MD

Chair, Quality Assurance; Section Head, Germ Cell Cancer; Associate Attending Physician, Genitourinary Oncology Service; Associate Professor of Medicine, Weill Cornell Medical College

#### DEVIKA GAJIRIA, MD

Assistant Attending Physician, Breast Medicine Service

#### MARK B. GEYER, MD

Adolescent and Young Adult Program Leader; Assistant Attending, Leukemia Service & Cellular Therapy Service; Assistant Professor of Medicine, Weill Cornell Medicine

#### MRINAL M. GOUNDER, MD

Associate Attending Physician, Sarcoma Medical Oncology & Early Drug Development (Phase I); Physician Ambassador, India and Asia, Bobst International Center, MSK

#### RACHEL N. GRISHAM, MD

Section Head, Ovarian Cancer; Director, Gynecologic Medical Oncology, MSK Westchester; Associate Attending Physician, Gynecologic Medical Oncology Service

#### MALIN HULTCRANTZ, MD

Assistant Attending Physician, Myeloma Service; Assistant Professor of Medicine, Weill Cornell Medicine

#### GOPA IYER, MD

Section Head, Bladder Cancer; Associate Attending Physician, Genitourinary Oncology Service & Early Drug Development Service

#### THOMAS J. KALEY, MD

Vice Chair, Department of Neurology; Associate Attending Neuro-Oncologist

#### SIMON MANTHA, MD, MPH

Attending Physician, Hematology Service

#### MICHAEL J. MAURO, MD

Leader, Myeloproliferative Neoplasms Program; Attending Physician, Leukemia Service

#### JODI V. MONES, MD

Associate Fellowship Program Director; Cellular Therapy Service Associate Attending Physician, Hematology Service

#### ALISON J. MOSKOWITZ, MD

Associate Attending Physician, Lymphoma Service

#### **ROBERT J. MOTZER, MD**

Section Head, Kidney Cancer; Jack and Dorothy Byrne Chair in Clinical Oncology; Attending Physician, Genitourinary Oncology Service

#### EILEEN M. O'REILLY, MD

Winthrop Rockefeller Endowed Chair in Medical Oncology; Co-Director, Medical Initiatives, David M. Rubenstein Center for Pancreatic Cancer Research; Section Head, Hepatopancreaticobilary & Neuroendocrine Cancers; Attending Physician, Member, Gastrointestinal Oncology Service; Professor of Medicine, Weill Cornell Medical College

#### **REKHA PARAMESWARAN, MD**

Attending Physician, Hematology Service

#### **GREGORY J. RIELY, MD, PHD**

Vice Chair, Clinical Research; Attending Physician, Thoracic Oncology Service

#### LINDSEY ROEKER, MD

Assistant Attending Physician, Leukemia Service

#### LEONARD SALTZ, MD

Executive Director for Clinical Value & Sustainability; Head, Colorectal Oncology Section; Attending Physician, Gastrointestinal Oncology Service; Professor of Medicine, Weill Cornell Medical Center

#### **RACHEL SANFORD, MD**

Assistant Attending Physician, Breast Medicine Service

#### MICHAEL SCORDO, MD

Assistant Attending Physician, Bone Marrow Transplant Service & Cellular Therapy Service

#### SUSAN K. SEO, MD

Director, Antibiotic Management Program; Assistant Attending Physician, Attending Physician. Infectious Disease Service

#### **GUNJAN L. SHAH, MD**

Assistant Attending Physician. Bone Marrow Transplant Service & **Cellular Therapy Service** 

#### SUSAN F. SLOVIN, MD, PHD

Associate Vice Chair, Academic Affairs; Attending Physician. Genitourinary Oncology Service & **Cellular Therapy Service** 

#### ZSOFIA K. STADLER, MD

Clinical Director, Clinical Genetics Service; Attending Physician, Associate Attending Physician, **Clinical Genetics Service &** Gastrointestinal Oncology Service

#### EYTAN M. STEIN, MD

Chief, Leukemia Service; Director, Program for Drug Development in Leukemia

#### ANNA M. VARGHESE, MD

Gastrointestinal Oncology Service

#### CY R. WILKINS, MD

Assistant Attending Physician, Hematology Service; Assistant Professor of Clinical Medicine, Weill Cornell Medical College

#### MARJORIE G. ZAUDERER, MD

Co-Director MSK Mesothelioma Program; Associate Attending Physician, Thoracic Oncology Service

#### ANDREW D. ZELENETZ, MD, PHD

Medical Director, Quality Informatics; Lymphoma Service

## MITIGATION OF RELEVANT FINANCIAL RELATIONSHIPS

Memorial Sloan Kettering Cancer Center adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all financial relationships with ineligible companies (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of the activity.

# Schedule

All times listed are Eastern Standard Time (EST).

## DAY 1 • Friday, March 10, 2023

8:45 AM	Attendee Zoom Sign-On
9:00 am	Introduction and Welcome David H. Ilson, MD, PhD, FACP, FASCO
SOLID TU	MOR SESSION
9:15 ам	COLON CANCER Leonard Saltz, MD
10:00 ам	MELANOMA Paul B. Chapman, MD
10:45 ам	PROSTATE CANCER Susan F. Slovin, MD, PhD
11:30 ам	KIDNEY CANCER Robert J. Motzer, MD
12:15 рм	MESOTHELIOMA Marjorie G. Zauderer, MD
12:30 рм	Lunch Break
1:15 рм	UROTHELIAL CANCER Gopa Iyer, MD
2:00 рм	TESTIS CANCER Darren R. Feldman, MD
2:45 рм	UTERINE/CERVIX/OTHER GYN CANCERS Carol Aghajanian, MD
3:30 рм	Break
3:45 рм	OVARIAN CANCER Rachel N. Grisham, MD
4:30 рм	BREAST CANCER: SURGERY Hiram S. Cody III, MD, FACS
5:00 рм	BREAST CANCER: RADIATION THERAPY Lior Z. Braunstein, MD
5:30 рм	GENETICS Zsofia K. Stadler, MD
6:00 рм	Closing Remarks & Adjourn David H. Ilson, MD, PhD, FACP, FASCO

## DAY 2 • Saturday, March 11, 2023

6:45 ам	Attendee Zoom Sign-On
6:55 ам	Day 2 Introduction David H. Ilson, MD, PhD, FACP, FASCO
7:00 am	SMALL CELL LUNG CANCER Noura J. Choudhury, MD
7:30 ам	BREAST CANCER: ADJUVANT THERAPY Chau T. Dang, MD
8:30 am	BREAST CANCER: ADVANCED DISEASE Rachel Sanford, MD
9:30 ам	<b>BREAST CANCER: HORMONAL THERAPY</b> Devika Gajria, MD
10:00 am	CARCINOMA OF UNKNOWN PRIMARY Anna M. Varghese, MD
10:30 ам	Break
10:45 ам	HEPATOCELLULAR CANCER & CHOLANGIOCARCINOMA Ghassan K. Abou-Alfa, MD
11:30 ам	PANCREATIC & NEUROENDOCRINE CANCER Eileen M. O'Reilly, MD
12:15 рм	Lunch Break
1:00 рм	NON SMALL CELL LUNG CANCER Gregory J. Riely, MD, PhD
2:00 рм	HEAD & NECK, THYROID, & NON-MELANOMA SKIN CANCER Lara A. Dunn, MD
3:00 рм	ANAL/RECTAL CANCER Andrea Cercek, MD
3:30 рм	Break
3:45 рм	ESOPHAGEAL/GASTRIC CANCER David H. Ilson, MD, PhD, FACP, FASCO
4:30 рм	<b>CNS TUMORS</b> Thomas J. Kaley, MD
5:00 рм	SARCOMA Mark A. Dickson, MD
5:30 рм	INFECTIOUS DISEASE Susan K. Seo, MD
6:00 рм	Closing Remarks & Adjourn David H. Ilson, MD, PhD, FACP, FASCO

## DAY 3 • Sunday, March 12, 2023

7:15 ам	Attendee Zoom Sign-On
7:25 ам	Day 3 Introduction Paul A. Hamlin, MD
7:30 ам	PHARMACOLOGY I Mrinal M. Gounder, MD
8:15 ам	PHARMACOLOGY II Mrinal M. Gounder, MD
9:00 AM	Break
MALIGNA	NT HEMATOLOGY SESSION
9:15 ам	CAR T CELLS Michael Scordo, MD
10:10 ам	LOW-GRADE NON-HODGKIN LYMPHOMA (NHL) Andrew D. Zelenetz, MD, PhD
10:40 ам	CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/ SMALL LYMPHOCYTIC LYMPHOMA (SLL) Lindsey Roeker, MD
11:10 ам	DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)/ MANTLE CELL LYMPHOMA (MCL)/ BURKITT LYMPHOMA (BL) Paul Hamlin, MD
12:10 рм	Lunch Break
12:40 рм	HODGKIN LYMPHOMA (HL)/T CELL Alison Moskowitz, MD
1:40 рм	AUTO/ALLO Gunjan Shah, MD
2:10 рм	ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) Mark Blaine Geyer, MD
2:40 рм	ACUTE MYELOID LEUKEMIA (AML) Eytan Stein, MD
3:10 рм	Break
3:40 рм	MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASMS (MDS/MPN) Michael J. Mauro, MD
4:40 рм	MYELOMA/AMYLOID Malin Hultcrantz, MD, PhD
5:40 рм	Closing Remarks & Adjourn Paul A. Hamlin, MD

## DAY 4 • Monday, March 13, 2023

7:45 ам	Attendee Zoom Sign-On			
8:00 am	Day 4 Introduction Paul A. Hamlin, MD			
BENIGN HEMATOLOGY SESSION				
8:05 am	APPROACH TO THE BLEEDING PATIENT Rekha Paramewaran, MD			
9:00 am	THE ROLE OF DIRECT ORAL ANTICOAGULANTS IN PRACTICE Simon Mantha, MD, MPH			
10:00 ам	THROMBOCYTOPENIA, ITP & BEYOND Cy Wilkins, MD			
11:00 ам	SICKLE CELL DISEASE, THALASSEMIA Jodi Mones, MD			
12:00 рм	Closing Remarks & Adjourn Paul A. Hamlin, MD			

## ACCREDITATION

Memorial Sloan Kettering Cancer Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

## AMA CREDIT DESIGNATION STATEMENT

Memorial Sloan Kettering Cancer Center designates this enduring material for a maximum of 30.75 AMA PRA Category 1 Credits<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

## ABIM MOC RECOGNITION STATEMENT

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 30.75 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting CME MOC ABIM MOC credit.





## **REGISTER ONLINE:**

## mskcc.org/HemOncBoardReview

## **REGISTRATION FEES**

Physicians (MDs, PhDs, & DOs)	\$1,650
Residents, Fellows, Nurses, & Other Healthcare Providers	\$1,075
Industry Professionals*	\$2,885

\*Industry professionals may attend MSK CME activities for their own education. Marketing, sales, and promotion of products and services is strictly prohibited at MSK CME activities.

### **DISCOUNTS/PROMOTIONS**

- Registration is complimentary for all MSK employees.
- A 30% discount is available for MSK Alumni and MSK Cancer Alliance members
- A limited number of complimentary registration spots for the 2023 HemOnc Board Review are available for MSK International Observers as well as graduate students and practicing oncologists in India. Interested providers who are part of these two international groups must apply for consideration. Approved applicants will be notified of their acceptance of complimentary registration by March 1, 2023.

For additional details, including the MSK CME cancellation policy, visit the course website: **mskcc.org/HemOncBoardReview** 



Memorial Sloan Kettering Cancer Center